← Leaderboards
Kunal Rai
Dana-Farber Cancer Inst
$10,112,166
Attributed
$14,413,313
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2011–25$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,413,313 · 10
By mechanism
R01$7,599,602 · 4
UG3$2,717,589 · 1
UH3$2,270,520 · 1
R21$794,122 · 2
R00$747,000 · 1
K99$284,480 · 1
Top collaborators
- Maria Pia Morelli3 shared
- Helen M Piwnica-Worms3 shared
- Cassian Yee3 shared
Others in their field
Top investigators on “Epigenetic Process”
- James E. Gern · University Of Wisconsin-Madison$115,652,679
- Richard A Gibbs · Baylor College Of Medicine$86,065,396
- Lisa P Jacobson · Johns Hopkins University$67,179,266
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$58,922,015
- Leonardo Trasande · New York University School Of Medicine$52,109,279
- Linda M Brzustowicz · Rutgers The St Univ Of Nj New Brunswick$47,855,284
Research focus
Epigenetic ProcessCellsMediatingGenesGene ExpressionMalignant NeoplasmsEpigenomicsKnock-DownExperimental StudyEpigenomePhenotypeChromatinMouse ModelTumorCell LineIn VivoProteinsInsightGeneticMelanomaComplexRegulationIn VitroNeoplasm Metastasis
Grant awards (29)
HORMAD-specific TGF-beta resistant memory T cells for treatment of patients with Gastro-esophageal Cancer$2,270,520
UH3 · FY2025 · CA
Mechanisms of fasting-induced radioprotection of small intestinal epithelial cells$661,519
R01 · FY2025 · CA
HORMAD-specific TGF-beta resistant memory T cells for treatment of patients with Gastro-esophageal Cancer$1,310,673
UG3 · FY2024 · CA
Mechanisms of fasting-induced radioprotection of small intestinal epithelial cells$628,444
R01 · FY2024 · CA
UCHL5 as a regulator and therapeutic target in metastatic melanoma$390,885
R01 · FY2024 · CA · contact PI
Role of UBR7, a novel H2BK120 E3 ubiquitin ligase, in suppression of breast cancer$352,047
R01 · FY2024 · CA · contact PI
HORMAD-specific TGF-beta resistant memory T cells for treatment of patients with Gastro-esophageal Cancer$1,406,916
UG3 · FY2023 · CA
Mechanisms of fasting-induced radioprotection of small intestinal epithelial cells$661,519
R01 · FY2023 · CA
UCHL5 as a regulator and therapeutic target in metastatic melanoma$403,230
R01 · FY2023 · CA · contact PI
Role of UBR7, a novel H2BK120 E3 ubiquitin ligase, in suppression of breast cancer$363,164
R01 · FY2023 · CA · contact PI
UCHL5 as a regulator and therapeutic target in metastatic melanoma$403,228
R01 · FY2022 · CA · contact PI
Role of UBR7, a novel H2BK120 E3 ubiquitin ligase, in suppression of breast cancer$363,164
R01 · FY2022 · CA · contact PI
Role of KMT2D and aberrant enhancers in modulating tumor microenvironment in melanoma$358,680
R01 · FY2022 · CA · contact PI
Contribution of Epigenome to PRKCI-Driven High-Grade Serous Ovarian Cancer$416,543
R21 · FY2021 · CA · contact PI
UCHL5 as a regulator and therapeutic target in metastatic melanoma$411,457
R01 · FY2021 · CA · contact PI
Role of UBR7, a novel H2BK120 E3 ubiquitin ligase, in suppression of breast cancer$370,575
R01 · FY2021 · CA · contact PI
Role of KMT2D and aberrant enhancers in modulating tumor microenvironment in melanoma$366,000
R01 · FY2021 · CA · contact PI
UCHL5 as a regulator and therapeutic target in metastatic melanoma$408,096
R01 · FY2020 · CA · contact PI
Role of UBR7, a novel H2BK120 E3 ubiquitin ligase, in suppression of breast cancer$370,575
R01 · FY2020 · CA · contact PI
Role of KMT2D and aberrant enhancers in modulating tumor microenvironment in melanoma$366,000
R01 · FY2020 · CA · contact PI
Role of KMT2D and aberrant enhancers in modulating tumor microenvironment in melanoma$355,019
R01 · FY2019 · CA · contact PI
Co-operative roles for YAP1 and UCHL5 in cancer progression and therapy$168,779
R21 · FY2019 · CA · contact PI
Role of KMT2D and aberrant enhancers in modulating tumor microenvironment in melanoma$366,000
R01 · FY2018 · CA · contact PI
Co-operative roles for YAP1 and UCHL5 in cancer progression and therapy$208,800
R21 · FY2018 · CA · contact PI
Epigenetics of Melanoma Metastasis$249,000
R00 · FY2017 · CA · contact PI
Epigenetics of Melanoma Metastasis$249,000
R00 · FY2016 · CA · contact PI
Epigenetics of Melanoma Metastasis$249,000
R00 · FY2015 · CA · contact PI
Epigenetics of Melanoma Metastasis$142,560
K99 · FY2012 · CA · contact PI
Epigenetics of Melanoma Metastasis$141,920
K99 · FY2011 · CA · contact PI